Tirzepatide Side Effects: The Hair-Loss Question, the GI Adjustment, and What's Actually Serious

What are the most common side effects of tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates two hormonal pathways that slow digestion and turn down appetite signaling at the same time, and nearly everything on the common side-effect list traces back to that one mechanism working as intended.

• Nausea — the most common complaint, strongest right after each dose increase
• Diarrhea — reported somewhat more often with tirzepatide than with GLP-1-only drugs
• Constipation — sometimes alternating with diarrhea at different points in treatment
• Vomiting — less common than nausea, more likely early on
• Decreased appetite, mild abdominal pain, or reflux
• Fatigue or mild headache, particularly if food intake drops sharply
• Injection-site redness or irritation, for the injectable forms

In the SURMOUNT-1 trial that supported approval, nausea affected roughly a quarter to a third of participants depending on the dose. Diarrhea ran somewhat lower, around 17% to 23%. Constipation landed at 11% to 17%, and vomiting at 6% to 13%. All four were heaviest during the dose-escalation phase and eased afterward.

Compared with semaglutide, a GLP-1-only drug, tirzepatide's added GIP-receptor activity is thought by some researchers to soften the nausea signal a little, though the class-wide comparison isn't fully settled, and tirzepatide's diarrhea numbers tend to run a bit higher in exchange. In practice, the total GI burden across the two drugs looks similar — it's just distributed slightly differently across symptoms.

Does tirzepatide cause hair loss?

This is the question that brings most people to this page, and it deserves a direct answer before anything else: in the trials that led to Zepbound's approval, hair loss was reported in roughly 5% of people on tirzepatide, against under 1% on placebo — a real, documented difference, and one large enough that alopecia is listed as an adverse reaction in the drug's FDA label. What that figure doesn't mean is that tirzepatide is attacking your hair follicles directly. There's no established mechanism by which the drug acts on hair growth itself.

What's actually happening, in the people who experience it, is telogen effluvium — a temporary, diffuse shedding pattern that follows any sufficiently fast weight loss, regardless of what caused it. Losing weight quickly pushes a larger share of hair follicles out of their growth phase and into a resting phase all at once, and a few months later, that resting hair sheds together instead of gradually. Because tirzepatide tends to produce some of the largest average weight-loss numbers among GLP-1 medications, this shedding pattern shows up in a larger share of tirzepatide users than it does with slower-acting drugs — a side effect of how well it works, not a side effect of the molecule attacking your hair.

Timing is fairly predictable: shedding tends to start a few months after the weight loss itself, not right when you start the medication, which is part of why it catches people off guard. It's also self-limiting for most people — once weight stabilizes and eating patterns normalize, hair density typically recovers over the following months. If you're also navigating perimenopausal thinning on top of this, that's worth untangling on its own terms — see perimenopause hair loss for the fuller mechanism and what actually helps.

Is tirzepatide safe?

The honest answer depends on which version you mean. Zepbound and Mounjaro are the same molecule — tirzepatide — sold under two different FDA approvals. Zepbound is approved specifically for chronic weight management. Mounjaro is approved for type 2 diabetes. When Mounjaro is prescribed for weight loss in someone without diabetes, that's off-label use of a drug studied and approved for a different condition — not untested, since it's the same active ingredient at similar doses, but outside the specific population the FDA reviewed for that use.

Compounded tirzepatide is a separate category again: pharmacy-mixed medication made by a licensed 503A pharmacy, not a product that has gone through the FDA's own premarket review as a finished drug. After the tirzepatide shortage was declared resolved in December 2024, broad shortage-era compounding wound down, leaving a narrower individual-patient pathway that requires a documented clinical reason the approved version won't work for that specific patient. For most healthy adults choosing among these three paths, the common side effects above are frequent but manageable, and the serious risks below are uncommon — the bigger safety-adjacent question is usually less about the molecule and more about which regulatory category you're comfortable with.

What are the serious side effects — does tirzepatide cause cancer?

A separate, shorter list sits below the everyday GI complaints — less frequent, and the reason tirzepatide carries the warnings it does.

• Pancreatitis — inflammation of the pancreas, observed in patients treated with GLP-1 receptor agonists including tirzepatide; the drug hasn't been studied in patients with a prior history of pancreatitis
• Gallbladder disease — gallbladder removal surgery was reported in a small share of tirzepatide-treated patients and essentially none on placebo in trials, with acute gallbladder events tied more to the pace of weight loss itself than to a direct drug effect
• Thyroid C-cell tumors — tirzepatide carries a boxed warning based on a two-year rodent study, where it caused a dose- and duration-dependent increase in thyroid C-cell tumors at clinically relevant exposures; whether this translates to humans hasn't been determined, and the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

On the direct cancer question: no confirmed case of thyroid C-cell tumors tied to tirzepatide or the wider GLP-1/GIP drug class has been reported in humans to date, and the boxed warning is specifically about the rare medullary type seen in rodents — not a signal of increased risk for the common thyroid cancers that make up most real-world diagnoses. That's a meaningfully different, and much less alarming, claim than "tirzepatide causes cancer," even though the two get conflated online. Longer-term cancer questions across this drug class more broadly — including pancreatic cancer — are still an area of active research rather than a settled one, which is a fair thing to sit with rather than resolve into false certainty either way.

Which side effects mean call a doctor the same day?

The everyday nausea-and-bloating cluster is one category. This is a different one — symptoms that overlap with the serious risks above and shouldn't wait for a routine follow-up message.

• Severe, persistent abdominal pain, especially if it radiates to your back, with or without vomiting — a possible sign of pancreatitis
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes — possible gallbladder involvement
• A new lump or swelling in your neck, persistent hoarseness, or trouble swallowing — the symptoms tied to the thyroid warning
• Signs of severe dehydration — very reduced urination, dizziness on standing, confusion — especially after several days of vomiting or diarrhea
• Signs of severe low blood sugar if you also take insulin or a sulfonylurea — shakiness, confusion, sweating that doesn't resolve with food

What are tirzepatide's long-term side effects?

Tirzepatide has been prescribed as Mounjaro for type 2 diabetes since 2022, which gives it a real track record in that original population. What's newer is the scale of weight-management use at Zepbound's doses, often for longer stretches than the original diabetes trials studied most closely — so some long-term questions are still genuinely being worked through rather than settled.

A meaningful share of the weight lost on tirzepatide is lean mass rather than fat, a pattern documented in body-composition sub-studies of the major trials. That matters more after 40, when perimenopause is already eroding muscle on its own — for the specific research and what actually helps protect muscle during treatment, see GLP-1s and muscle loss in perimenopause. Beyond muscle, researchers are still working out how years of sustained rapid weight loss affects bone density, and what happens metabolically for people who eventually stop the medication after using it long-term. None of that is a reason to assume a hidden danger — it's simply the honest state of a newer, larger-scale use of a drug whose diabetes indication is older and better mapped.

Do injections and the oral (compounded) version have different side effects?

Rotating your injection site — thigh, abdomen, back of the arm — week to week is the simplest way to avoid the redness and irritation that builds up from repeatedly using the same spot, and it doesn't change anything about the drug's broader side-effect profile.

The oral question is a bigger one. As of 2026, there is no FDA-approved oral tirzepatide — Zepbound and Mounjaro are both injectable, full stop. Anything sold online as an oral tirzepatide tablet, troche, capsule, or drop is a compounded product from a 503A pharmacy, not an FDA-approved finished drug. That distinction matters more here than it does for some other GLP-1s: tirzepatide is a peptide that digestive enzymes break down before it can be absorbed, and unlike oral semaglutide (which pairs the drug with an FDA-approved absorption-enhancing formulation in Rybelsus), there's no equivalent, publicly validated formulation established for oral tirzepatide specifically. That means how much of a compounded oral dose actually reaches your bloodstream is less predictable than an injection — worth asking any provider offering it directly how they've addressed that, rather than assuming it behaves like the injectable version at an equivalent dose.

What do real tirzepatide users say about side effects?

Across GLP-1 forums and provider review sites, a few patterns repeat often enough to be worth naming, even without pointing to any single account. The first weeks generate the most complaints — nausea and appetite loss dominate, and people who slow down their own titration pace (with their provider's input) tend to report an easier stretch than those who push through faster than recommended. Hair-shedding threads cluster a few months after someone reports their biggest drop in weight, not right after starting — which lines up with the telogen-effluvium timing described above rather than an immediate drug reaction. A smaller but consistent thread involves protein intake and muscle loss concerns, especially among people prioritizing the scale number over how their clothes fit or how they feel doing daily activities. Separately from the drug itself, sentiment about individual telehealth providers varies more on customer service, shipping reliability, and billing clarity than on the medication's effects — worth remembering when a bad review is really about the company, not the molecule.

How do you manage tirzepatide side effects day to day?

A handful of practical habits cover most of what shows up in the first weeks.

• Respect the titration schedule — dose increases are spaced out specifically to give your gut time to adjust; asking to move faster tends to backfire
• Go smaller and lower-fat with meals — tirzepatide already slows digestion, and a large or fatty meal on top of that is the most common trigger for nausea
• Stay ahead of hydration, especially during a rough stretch of vomiting or diarrhea
• Prioritize protein at each meal — it supports satiety and helps protect lean muscle during a period of reduced overall intake
• Rotate your injection site each week rather than reusing the same spot
• Track when nausea tends to peak — some people do better injecting at a specific time of day once they notice the pattern

Where to get tirzepatide if a side effect needs closer monitoring

If a symptom is dragging past the first couple of months, or you'd rather have a provider adjust your pace than push through alone, the real differences between programs show up less in the sticker price and more in what's already included once you're enrolled.

Curex posts the lowest verified all-in starter price and offers both oral and injectable compounded tirzepatide — a genuine option if injection-site irritation specifically is what's bothering you, though ask for the maintenance-dose price ladder in writing before enrolling, since the $199 figure is a starting point rather than the steady-state number.

Mochi Health keeps its medication price flat at every dose, which is useful specifically if your provider slows your titration to manage a side effect — the bill doesn't change with the pace. Henry Meds is one of the few programs offering a genuine oral track alongside the injection, bundled into one all-in price with no separate membership fee.

Fridays bundles dietitian access and group coaching into its price — useful if appetite changes or nausea are making meal planning genuinely hard, not just an inconvenience — though the lowest rate requires a year's commitment, so read the refund terms first. For the FDA-approved option with no compounded-status question at all, LillyDirect's self-pay Zepbound vials are the only brand-name pathway here, with a strict 45-day refill window to hold the lower price.